To evaluate risk factors and outcomes of spondylodiscitis in hemodialysis patients.

Retrospective case control study of twenty-two spondylodiscitis patients and forty-four control subjects.

The incidence of spondylodiscitis was 8.3 cases per 1000 patient-years. Spondylodiscitis patients had been receiving hemodialysis for a significantly longer average duration (median, thirty-seven months) than control subjects (median, thirteen months; P < 0.0008). A greater proportion of spondylodiscitis patients (eighteen [82%] patients) than control subjects (six [14%] subjects; P < 0.0001) had microorganism growth from at least one blood culture within three months before diagnosis of spondylodiscitis. During the months before spondylodiscitis diagnosis, a significantly greater proportion of spondylodiscitis patients than control subjects had received blood products, had an invasive procedure, had any type of vascular access established, or had temporary or permanent internal jugular or temporary femoral central venous catheters placed. All patients with spondylodiscitis received antimicrobial therapy (mean duration, twenty-one ± fourteen weeks). The death rate was significantly greater for spondylodiscitis patients (thirteen [59%] patients) than control subjects (twelve [28%] subjects; P < 0.03; odds ratio, 2.69; 95% confidence interval, 1.03 to 7.04).

Risk factors for spondylodiscitis in hemodialysis patients include antecedent bacteremia, receipt of blood products, invasive procedures, or establishment of vascular access. Spondylodiscitis in hemodialysis patients has a poor prognosis and high risk of mortality.